Chedid Maroun, Kaidbay Hasan-Daniel, Wigerinck Stijn, Mkhaimer Yaman, Smith Byron, Zubidat Dalia, Sekhon Imranjot, Prajwal Reddy, Duriseti Parikshit, Issa Naim, Zoghby Ziad M, Hanna Christian, Senum Sarah R, Harris Peter C, Hickson LaTonya J, Torres Vicente E, Nkomo Vuyisile T, Chebib Fouad T
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Lebanese American University, Gilbert and Rose-Mary Chagoury school of medicine, Byblos, Lebanon.
Kidney Int Rep. 2022 Jun 11;7(9):1991-2005. doi: 10.1016/j.ekir.2022.06.006. eCollection 2022 Sep.
Cardiovascular disease leads to high morbidity and mortality in patients with kidney failure. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disease with various cardiac abnormalities. Details on the cardiovascular profile of patients with ADPKD who are undergoing kidney transplantation (KT) and its progression are limited.
Echocardiographic data within 2 years before KT (1993-2020), and major adverse cardiovascular events (MACEs) after transplantation were retrieved. The primary outcome is to assess cardiovascular abnormalities on echocardiography at the time of transplantation in ADPKD as compared with patients without ADPKD matched by sex (male, 59.4%) and age at transplantation (57.2 ± 8.8 years).
Compared with diabetic nephropathy (DN, 271) and nondiabetic, patients without ADPKD (NDNA) ( 271) at the time of KT, patients with ADPKD ( 271) had lower rates of left ventricular hypertrophy (LVH) (39.4% vs. 66.4% vs. 48.6%), mitral (2.7% vs. 6.3% vs. 7.45) and tricuspid regurgitations (1.8% vs. 6.6% vs. 7.2%). Patients with ADPKD had less diastolic (25.3%) and systolic (5.6%) dysfunction at time of transplantation. Patients with ADPKD had the most favorable post-transplantation survival (median 18.7 years vs. 12.0 for diabetic nephropathy [DN] and 13.8 years for nondiabetic non-ADPKD [NDNA]; < 0.01) and the most favorable MACE-free survival rate (hazard ratio = 0.51, < 0.001). Patients with ADPKD had worsening of their valvular function and an increase in the sinus of Valsalva diameter post-transplantation (38.2 vs. 39.9 mm, < 0.01).
ADPKD transplant recipients have the most favorable cardiac profile pretransplantation with better patient survival and MACE-free survival rates but worsening valvular function and increasing sinus of Valsalva diameter, as compared with patients with other kidney diseases.
心血管疾病导致肾衰竭患者的高发病率和高死亡率。常染色体显性多囊肾病(ADPKD)是一种伴有各种心脏异常的全身性疾病。关于接受肾移植(KT)的ADPKD患者的心血管状况及其进展的详细信息有限。
检索KT前2年(1993 - 2020年)的超声心动图数据以及移植后的主要不良心血管事件(MACE)。主要结局是评估ADPKD患者在移植时超声心动图上的心血管异常情况,并与按性别(男性,59.4%)和移植时年龄(57.2±8.8岁)匹配的非ADPKD患者进行比较。
与糖尿病肾病(DN,271例)和非糖尿病的非ADPKD患者(NDNA,271例)在KT时相比,ADPKD患者(271例)左心室肥厚(LVH)发生率较低(39.4%对66.4%对48.6%),二尖瓣反流(2.7%对6.3%对7.45%)和三尖瓣反流发生率较低(1.8%对6.6%对7.2%)。ADPKD患者在移植时舒张功能障碍(25.3%)和收缩功能障碍(5.6%)较少。ADPKD患者移植后生存率最有利(中位生存期18.7年,糖尿病肾病[DN]为12.0年,非糖尿病非ADPKD[NDNA]为13.8年;P<0.01),无MACE生存率最有利(风险比 = 0.51,P<0.001)。ADPKD患者移植后瓣膜功能恶化,主动脉窦直径增加(38.2对39.9mm,P<0.01)。
与其他肾病患者相比,ADPKD移植受者移植前心脏状况最有利,患者生存率和无MACE生存率更高,但瓣膜功能恶化,主动脉窦直径增加。